Dipivefrine - CAS 52365-63-6
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dipivefrine is a prodrug of adrenaline and is used to treat glaucoma. It penetrates the cornea and is then hydrolysed to epinephrine by esterase enzymes. It increases outflow of the aqueous humour and reduces its formation, thus reducing pressure inside the eye. It also increases the conductivity of trabecular filtering cells. It has been listed.
Publictions citing BOC Sciences Products
  • >> More
Solid powder
[2-(2,2-Dimethylpropanoyloxy)-4-(1-hydroxy-2-methylamino-ethyl)- phenyl] 2,2-dimethylpropanoate;Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester;K30081;K-30081;Dipivefrinum;Dipivefrina;4-(1-Hydroxy-2-(methylamino)ethyl
Soluble in DMSO, not in water
-20°C Freezer
Dipivefrine is used to treat glaucoma.
Quality Standard:
In-house standard
Boiling Point:
473.7±45.0 °C | Condition: Press: 760 Torr
Melting Point:
146-147 °C
1.097±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Dipivefrine has been listed.
1.[The effect of three kinds of anti-glaucoma eyedrops on ocular blood flow].
Zhao J1, Mao J, Sui R. Zhonghua Yan Ke Za Zhi. 2000 Nov;36(6):425-30.
OBJECTIVE: Surveying the changes of ocular blood flow by continuous anti-glaucoma eyedrops for one week.
2.Pupillary supersensitivity and visual disturbance in Parkinson's disease.
Hori N1, Takamori M, Hirayama M, Watanabe H, Nakamura T, Yamashita F, Ito H, Mabuchi N, Sobue G. Clin Auton Res. 2008 Feb;18(1):20-7. doi: 10.1007/s10286-008-0453-4. Epub 2008 Feb 11.
This study evaluated pupillary postganglionic autonomic dysfunction and its relationship to visual disturbance in idiopathic Parkinson's disease (PD). Pupillary sensitivity was examined in relation to a parasympathomimetic agent [0.05% pilocarpine hydrochloride (PL)] and to a sympathomimetic agent [0.02% dipivefrine hydrochloride (DPE)] using infrared pupillography in 40 PD patients and 17 age-matched controls. Visual disturbances were evaluated as well, including blurring, photophobia, night blindness and involuntary eyelid closure in response to light. Pupillary supersensitivity to PL and DPE and their relation to visual disturbances were found to be significantly greater in PD patients than in controls (22.3 +/- 15.1 vs. 10.4 +/- 11.4%, P < 0.005, and14.5 +/- 14.5 vs. 4.9 +/- 8.7%, P < 0.01, respectively). In addition, pupillary sympathetic supersensitivity did not correlate with a reduction of 123I-metaiodobenzylguanidine (MIBG) cardiac accumulation.
3.Latanoprost: new preparation. Antiglaucoma eye drops that can change the colour of the iris.
Prescrire Int. 1998 Dec;7(38):166-8.
(1) Latanoprost, a prostaglandin F2 alpha analogue, is an antiglaucoma drug. (2) The clinical file is fairly thorough. (3) Dose-finding studies show that the optimal daily dose is a single drop of 0.005% solution, preferably in the evening. Two drops a day are less effective than one drop a day. (4) The local hypotensive action of latanoprost persists in the long term (current follow-up one year). (5) Four double-blind trials have compared 0.005% latanoprost eye drops and 0.5% timolol eye drops. In three trials the effect of latanoprost on intraocular pressure was statistically stronger than that of timolol. However, the difference in mean intraocular pressure was less than 2 mm Hg between the two treatments, and the clinical relevance of such a difference is not known. (6) Latanoprost has not been compared with the other available antiglaucoma eye drops. (7) Various trials have shown that intraocular pressure is statistically lower when latanoprost is combined with another antiglaucoma eye drop preparation (timolol, pilocarpine or dipivefrine) than during monotherapy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 52365-63-6 Dipivefrine

Quick Inquiry

Verification code

Featured Items